China-Pak strategic partnership signed to advance CAR-T therapy in Pakistan showcasing willingness to cooperation on the strengths of each country.
A strategic cooperation agreement was signed in Beijing on October 17 among Beijing Yuanxin Huibao Technology Co., Ltd., the Pakistan China Business Association, and Nanjing IASO Biotechnology Co., Ltd. The goal is to improve the availability of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for adult patients with multiple myeloma in Pakistan.
At the signing ceremony, Tahir Farooq, President of the Pakistan China Business Association, emphasized that the partnership would introduce advanced CAR-T Therapy to Pakistan while also implementing innovative payment models to reduce financial strain and increase access to the treatment.
Additionally, Eric Tian, head of overseas operations at IASO Biotechnology, explained that the alliance would combine the strengths of each partner to foster the development of innovative medical treatments and enhance the efficiency of CAR-T services for Pakistani patients.
Moreover, CAR-T Therapy is considered a breakthrough in cell therapy, especially for treating blood cancers. Peng Xuan, CEO of Yuanxin Huibao, highlighted that the collaboration will greatly enhance the accessibility of CAR-T treatments, allowing more Pakistani patients to benefit from this advanced therapy.
Related Posts
China-Pakistan boosting cooperating for sustainable development in medical sector
